Navigation Links
Experimental Treatment Could Fight Muscular Dystrophy
Date:8/25/2009

In some patients, injected molecule appears to restart production of missing protein

TUESDAY, Aug. 25 (HealthDay News) -- Injecting a therapeutic molecule into muscle appears to jump-start the production of a crucial protein that's missing in patients with Duchenne muscular dystrophy, British researchers report.

The treatment so far is only applicable to about 13 percent of people with the debilitating and ultimately fatal disease, but scientists are hopeful that similar molecules might expand the treatment to a wider range of patients.

Duchenne muscular dystrophy affects about one in 3,500 males, and involves a progressive wasting of muscle due to a genetic inability to produce the protein dystrophin, a key component of muscle structure. No treatments are available for the illness, and most of those affected die by age 30.

Recently, molecules called antisense oligonucleotides have shown some promise. These molecules work by "skipping over" portions of the defective gene that would otherwise block dystrophin production.

In their study, published online Aug. 25 in The Lancet Neurology, researchers at the University College London Institute of Child Health selected seven patients for whom a particular oligonucleotide molecule, called AVI-4658, appeared suitable. In these patients, the molecule "skipped" exon 51 -- the portion of the dystrophin-blocking gene that appeared to get in the way of effective dystrophin production.

Injecting the molecule into the muscles of these seven patients resulted in increased dystrophin production in all treated muscles, according to a journal news release. "Intramuscular AVI-4658 was safe and induced the expression of dystrophin locally within treated muscles," the team wrote. "On the basis of these observations, we have initiated a dose-ranging study to assess the safety and efficacy of repeated doses of systemic intravenous AVI-4658."

In a commentary, Annemieke Aartsma-Rus and Gert-Jan van Ommen, from Leiden, the Netherlands, noted that while only about 13 percent of Duchenne muscular dystrophy patients can be expected to be helped by AVI-4658, molecules that skip other exons on the gene could be used, potentially spreading the benefit to more than 70 percent of patients.

More information

Find out more about Duchenne muscular dystrophy at the Muscular Dystrophy Association.



-- E.J. Mundell



SOURCE: The Lancet Neurology, news release, Aug. 25, 2009


'/>"/>
Copyright©2009 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Experimental Urine Test Spots Appendicitis
2. Senetek PLC Gains Six Year Extension of Rights from Czech Republic Institute of Experimental Botany
3. Experimental drug shows promise against head and neck cancer
4. Experimental agents may prevent radiation-induced leukemia
5. Experimental insulin-like growth factor receptor inhibitor reduced pancreatic cancer growth
6. Hard to Treat Diseases (HTDS) Releases experimental results in the treatment of (MS) Multiple Sclerosis
7. Experimental Drug May Dampen Severe Asthma
8. Experimental Drug May Prevent Plaque Buildup
9. Experimental Biology 2009 meets April 18-22
10. Experimental Weight-Loss Pill Passes Early Test
11. Experimental Drug Fights Bone Marrow Cancers
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Experimental Treatment Could Fight Muscular Dystrophy 
(Date:2/12/2016)... Angeles, CA (PRWEB) , ... February 12, 2016 , ... ... With a hectic schedule, a demanding job, and no time to decompress, Rabinowitz found ... she dedicated herself to meditation for its impact on her life, implementing a 20-minute-per-day ...
(Date:2/12/2016)... ... February 12, 2016 , ... The ... Zuckerberg San Francisco General Hospital on April 5-7. The series is a multi-day, ... new habits. The workshops cover a broad range of topics, including coaching skills, ...
(Date:2/12/2016)... ... February 12, 2016 , ... Fisher House Foundation Chairman and CEO Kenneth Fisher ... Military Support Alliance president Scott Bensing, and Peggy Kearns Director, VA Southern Nevada Healthcare ... System. This will be the first Fisher House in Nevada, and will provide ...
(Date:2/12/2016)... ... ... Vail knee specialist Robert LaPrade, MD, PhD was named one of ... of physicians establishing, leading and partnering with ambulatory surgery centers across the United States. ... also known as an ASC, is a modern health care facility focused on providing ...
(Date:2/12/2016)... ... February 12, 2016 , ... Donor Network West, the organ procurement organization ... a partnership with San Ramon Regional Medical Center. Under the collaboration, the first of ... way to accommodate a more certain time frame for donor families for the recovery ...
Breaking Medicine News(10 mins):
(Date:2/12/2016)... , Feb. 12, 2016 On Thursday, Feb. ... Surgery at St. David,s North Austin Medical Center successfully ... ® Xi ® Surgical System with Trumpf ... Thiru Lakshman , M.D., colorectal surgeon at ... proctocolectomy utilizing Integrated Table Motion technology, which seamlessly combines ...
(Date:2/12/2016)... , Feb. 12, 2016  Aralez Pharmaceuticals Inc. (Nasdaq: ... announced the Company will ring the Nasdaq Closing Bell ... New York at 4:00 p.m. ET on ... Aralez. Adrian Adams , will perform ... 3:50 to 4:00 p.m. ET.  A live webcast will ...
(Date:2/12/2016)... 2016  Apellis Pharmaceuticals, Inc., today announced ... Series D preferred stock financing, co-led by ... Group and venBio Global Strategic Fund, joining ... Investment, and Epidarex Capital. The proceeds of the ... clinical trials in the Company,s ongoing complement ...
Breaking Medicine Technology: